Meitan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meitan

Quick Facts

Property Description
Active ingredient Diclofenac (as sodium or potassium salt)
Form Tablet (oral), injectable solution, topical gel, or patch
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common purpose Relief of pain, inflammation, and fever
Origin Synthetic compound (Phenylacetic acid derivative)

What Type of Medicine is Meitan (Diclofenac)?

Meitan is the trade designation for a synthetic medication containing the active ingredient Diclofenac, which is officially classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This classification denotes that the drug works by targeting chemical processes that cause discomfort and swelling. Diclofenac is structurally a derivative of Phenylacetic acid, a synthetic molecular class developed to modulate the inflammatory response. The distinction between Diclofenac sodium and Diclofenac potassium primarily differentiates its speed of absorption; for instance, the potassium salt is often utilized in formulations aiming for quicker relief.

Composition and Available Forms of Meitan

The efficacy of Meitan is derived from its sole active substance, Diclofenac, which is typically administered as one of its pharmaceutically acceptable salts. This drug is a single-active-ingredient preparation, meaning its composition focuses exclusively on the delivery of the Diclofenac component via multiple dosage forms. These forms include standard oral tablets (often enteric-coated for controlled release), injectable solutions, and localized preparations such as topical gels. Notably, the availability of a topical gel formulation offers flexibility in providing localized pain relief for conditions such as strains and sprains, a feature distinguishing it from strictly systemic oral medications.

What is the General Purpose of Meitan’s Action?

The general purpose of Meitan is to provide comprehensive symptomatic relief by exerting a three-pronged effect: anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) action. This function is achieved by inhibiting the activity of cyclooxygenase (COX) enzymes, which leads to a reduction in the synthesis of prostaglandins—the local hormone-like substances central to generating the body's inflammatory and pain responses. Diclofenac demonstrates strong inhibitory action on prostaglandin synthesis, which is the key to its core therapeutic property. By diminishing these key mediators, the medicine serves to alleviate the fundamental symptoms of soreness, swelling, and fever associated with various inflammatory processes.

What side effects are possible with Meitan?

Possible Side Effects and Safety Information

The safety profile of Meitan (Diclofenac) is defined by official regulatory documents, which categorize potential adverse effects by both the System-Organ Class (SOC) affected and the statistical frequency of occurrence. The highest frequency classifications for systemic use include effects such as headache, dizziness, nausea, vomiting, abdominal pain, diarrhea, and rash, which are listed as common.


Documented Serious Adverse Reactions

Official labeling highlights the potential for serious adverse reactions that are classified as rare or very rare. These include serious gastrointestinal (GI) events, such as bleeding, ulceration, and perforation of the stomach or intestines, which can occur at any time during treatment. Additionally, the drug carries a documented risk of cardiovascular thrombotic events, including myocardial infarction (MI) and stroke.

Severe reactions across other systems include hepatotoxicity (liver injury), serious skin reactions (such as Stevens-Johnson Syndrome, or SJS), and anaphylactic shock.


Safety Patterns and Restrictions

Regulatory safety information notes that the risk of serious cardiovascular events may increase with higher doses and longer duration of exposure. Use is strictly contraindicated in patients who have previously experienced allergic reactions (asthma, urticaria) after taking aspirin or other NSAIDs.

Population-specific safety considerations include a contraindication during the third trimester of pregnancy due to risk to the fetus and the requirement for caution in older adults, who face an increased risk of serious GI adverse events.

Overdose and Emergency Response

Overdose and when to seek help

This information is based strictly on documented overdose profiles and emergency guidance from government regulatory authorities.


Documented Overdose Manifestations

System Official Manifestations
Gastrointestinal Nausea, vomiting (possibly bloody), epigastric pain, diarrhea, and irritation
Neurological Drowsiness, confusion, dizziness, headache, lethargy, or tinnitus

Severe Outcomes and Emergency Action

An overdose may lead to severe, life-threatening outcomes, including seizures, coma, acute renal failure, and significant gastrointestinal bleeding or perforation, according to official labeling. Due to the risk of serious events, regulatory authorities mandate that immediate medical attention must be sought for any suspected overdose. Individuals should call their local emergency number or Poison Control Center immediately.

No specific pharmacological antidote is known for Meitan overdose. Management is officially described as symptomatic and supportive treatment, including the use of activated charcoal and gastric decontamination measures, if appropriate, and continuous hospital monitoring for vital signs and organ function is often required.

Therapeutic Uses of Meitan

What Meitan Treats: Main Uses and Benefits

Meitan (Diclofenac) is commonly used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed. It is considered relevant for managing symptoms that create noticeable physiological strain in chronic inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It also plays a role in managing symptoms related to sudden, disruptive episodes, including pain from minor soft tissue injuries, acute gout attacks, severe menstrual cramps, and migraine headaches.


This medication helps address symptom clusters that may intensify temporarily, such as joint pain, swelling, and stiffness, and is applied in addressing symptoms related to systemic imbalance, such as fever and generalized aching. This supports general well-being during symptomatic phases and may assist with maintaining functional stability.

“Meitan is commonly used to help with symptoms that create noticeable physiological strain, which helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Support for Pain, Inflammation, and Fever

Context Symptom Management Benefit to Patient
Chronic Joint Health Persistent pain, stiffness, and joint swelling Supports maintaining functional stability
Acute Episodic Pain Pain from injury, gout attacks, or migraines Helps with symptomatic relief during flare-ups
Systemic Discomfort Elevated body temperature and generalized aching Supports general well-being during episodes

Meitan is commonly used across conditions presenting with acute episodes and recurrent manifestations, including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gout, primary dysmenorrhea, and migraines.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Meitan?

The eligibility for Meitan (Diclofenac) is strictly defined by regulatory authorities, with use falling into three categories: allowed, restricted, or strictly contraindicated.


Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated and must not be used in several defined populations, including patients with:

  • Known hypersensitivity to Diclofenac or other NSAIDs (e.g., aspirin-sensitive asthma).
  • Active gastrointestinal ulceration, bleeding, or perforation.
  • Severe hepatic or severe renal impairment.
  • Established cardiovascular disease (e.g., CHF NYHA Class II-IV, IHD, or PAD).
  • Third trimester of pregnancy.
  • Peri-operative pain related to Coronary Artery Bypass Graft (CABG) surgery.

Conditional Use and Restrictions

Meitan use is restricted or not recommended for several populations, including:

  • Pediatric patients: Systemic use is generally not recommended below 14 to 16 years of age for most indications.
  • Older adult patients: Use requires extreme caution due to an increased risk of serious adverse events.
  • Pregnancy/Lactation: Not recommended in the first/second trimesters of pregnancy or while breastfeeding.
  • Mild-to-moderate impairment: Patients with mild-to-moderate renal or hepatic impairment or significant cardiovascular risk factors may only use Meitan under close medical supervision.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Meitan (Diclofenac) is documented by regulatory bodies, establishing constraints for co-administration with several medicinal product categories and substances.

Category Official Regulatory Statement
Contraindications Use is contraindicated in patients with a history of asthma, hives, or other allergic-type reactions after taking aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). It is also contraindicated for perioperative pain treatment in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Risk of Additive Toxicity Combining with Anticoagulants (e.g., Warfarin), Anti-platelet agents, SSRIs, or other NSAIDs substantially increases the documented risk of serious gastrointestinal bleeding or ulceration. Concurrent use with oral NSAIDs should generally be avoided.
Efficacy Reduction Meitan may diminish the antihypertensive effect of ACE Inhibitors and Angiotensin Receptor Blockers (ARBs), as well as reduce the natriuretic effect of Diuretics (e.g., Furosemide, Thiazides).
Altered Exposure Co-administration with strong CYP2C9 inhibitors, such as Voriconazole, is documented to significantly increase the systemic exposure (Cmax and AUC) of Meitan. Meitan can also increase the serum concentration and prolong the half-life of Digoxin.
Timing and Substances For specific oral formulations, food may cause a delay in the rate of absorption or a reduction in effectiveness. The use of alcohol is documented as a factor that increases the risk of gastrointestinal bleeding.
Population Note The interaction risk for deterioration of renal function with ACE Inhibitors or ARBs is highlighted as a concern in elderly, volume-depleted, or renally impaired patients.

Mechanism of Action

️ Core Action: Inhibiting Prostaglandin Synthesis

The drug's primary action is the non-covalent, reversible inhibition of Cyclooxygenase ( COX-1 and COX-2) enzymes. By blocking these enzymes, the drug halts the conversion of arachidonic acid into prostaglandins and related eicosanoids, which function as key chemical mediators that initiate vasodilation and neuronal sensitization. This mechanism results in the suppression of pro-inflammatory eicosanoid synthesis, which modifies localized tissue responses.


Dual-Effect Modulation of Pain Signaling

Meitan engages a secondary mechanism by acting as a modulator of Voltage-Dependent Sodium Channels found on nerve cell membranes. This mechanism reduces the excitability of the nerves, stabilizing the cell and limiting the propagation of pain signals in both the peripheral and central nervous systems. This non-prostaglandin-mediated action results in attenuation of pain signal transmission, which complements the effect of COX inhibition.


Regulating the Central Thermal Set Point

By suppressing COX activity in the hypothalamus, the central locus of thermoregulation, the drug reduces the local concentration of Prostaglandin E2 ( PGE2) in this brain region. This action influences the central thermostat, leading to a reduction in the febrile set point and modulation of the physiological thermal regulatory response.

Dosage and Administration Information

The use of Meitan (Diclofenac) is characterized by specific parameters across its various administration routes: oral tablets, localized topical preparations, and parenteral (IM/IV) solutions. A core principle for its application is to utilize the lowest effective dose for the shortest duration necessary.

Oral forms are available in strengths such as 50 mg or 75 mg, with the total daily systemic intake generally not exceeding 150 mg. Frequency ranges from once daily for extended-release versions to multiple times a day for immediate-release forms. Specific instructions apply to different oral versions; for instance, enteric-coated tablets are taken before meals, and certain oral powder packets must be mixed only with 1 to 2 ounces of plain water and consumed immediately. Tablets designed for controlled release must be swallowed whole and never crushed or chewed.

The topical gels are typically applied four times daily to the affected area. The parenteral route, used for acute, severe pain, is subject to specific constraints, such as limiting its administration to a maximum period of two days, followed by a transition to the oral form. Dose adjustments for older adults or in cases of hepatic or renal impairment often involve starting with the lowest possible dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Meitan (Diclofenac)

Evidence for Chronic Inflammatory Joint Conditions

Meitan was studied for its use in chronic conditions characterized by fluctuating or episodic manifestations, such as osteoarthritis and rheumatoid arthritis. This research includes numerous Randomized Controlled Trials (RCTs) and aggregated data from Systematic Reviews. These studies were conducted during periods of increased symptom activity, and research examined how patients reported their experiences with outcomes related to physical discomfort and limitations in daily functioning or activity level. These trials typically evaluated different formulations of Meitan, including both oral tablets and topical gels, against a neutral substance (placebo) or other treatments.

In these research scenarios, trials reported how symptoms evolved in the observed populations, and findings describe patterns observed in the studies regarding patient-reported changes in pain intensity and functional measures over the study period. While the evidence contributes to understanding symptom patterns over defined time intervals, the research generally focused on measuring changes in symptoms over periods of 12 weeks or less.

Long-term effects are not fully established regarding sustained functional stability or condition progression beyond the trial periods. There is limited information for long-term outcomes from controlled trials, and the variability in study outcomes, including the use of different patient-reported tools and formulations, means that certainty remains low when projecting outcomes over many years.


Evidence for Acute Pain and Localized Injuries

The research base, composed mainly of short-course RCTs and Meta-analyses, has explored how patient outcomes related to sudden, acute changes in pain intensity are measured following the use of Meitan, such as those in minor sprains, migraines, and acute gout attacks. This research base was evaluated in numerous short-course RCTs and Meta-analyses. These studies involved adults who were experiencing episodes where symptoms became more noticeable, with researchers focusing on outcomes describing episodic or acute changes, such as the time it took for patients to report changes in pain scores and the amount of symptom intensity reported in the hours following use.

Research describes patterns observed in the measured changes of reported pain scores compared to placebo, particularly with rapid-release oral formulations and topical formulations in localized injuries. These findings help contextualize how patients reported their experience during acute episodes. The studies monitored outcomes over very short intervals, sometimes just 24 to 48 hours, to capture the immediate response.

The evidence related to acute outcomes describing episodic or acute changes appears to be consistent in the short term. However, research is largely restricted to addressing temporary physiological imbalance. Comparative evidence is lacking across all available formulations and other available treatments for every single acute indication. Furthermore, there is limited information regarding whether studies explored changes in the frequency or severity of conditions presenting with cycles of stability and flare-ups (e.g., subsequent migraines or gout attacks).


Long-Term Studies and Follow-up Durations

The available research base includes a distinction between short-term symptom measurement studies and those attempting longer follow-up. Most pivotal Randomized Controlled Trials for Meitan have follow-up durations that were limited, typically lasting only a few weeks to measure immediate changes in outcomes related to physical discomfort. Research exploring how symptoms change over time in chronic conditions often has an intermediate-term focus of up to three months.

Extended data, sometimes derived from observational settings evaluating daily-life functioning, was observed in some studies to look at patterns over longer periods, but these settings often introduce factors that are more challenging to control than a dedicated clinical trial. The overall long-term effects are not fully established because large, controlled trials specifically designed to track chronic disease progression or sustained functionality over multiple years are not as commonly available as the shorter-term evidence.


Research in Specific Populations

Meitan was evaluated in patient populations across a broad age range, but data for certain groups remain insufficient across all groups. A significant portion of the evidence is drawn from studies of adults with established chronic joint conditions. Research was observed in trials exploring the use of topical formulations in older adults, where the application was studied for outcomes related to physical discomfort in superficial joints.

Data for certain groups remain insufficient. For instance, evidence for its use in pediatric populations for musculoskeletal pain relief is considerably limited compared to adult studies. Additionally, studies focusing exclusively on patients with significant comorbidities (multiple existing health issues) or specific, narrowly defined subgroups of severe disease activity are less common, meaning data for certain groups remain insufficient when attempting to generalize evidence to these specific groups. The results apply only to the populations studied, and researchers emphasize that patterns observed in one group may not be the same in another.


Understanding Evidence Gaps and Uncertainties

The existing evidence base, while extensive, highlights areas where knowledge is still developing. Evidence quality varies across studies, leading to situations where findings were mixed on certain outcomes or between different formulations. This is especially true when comparing how different oral forms or topical preparations appear to address different types of pain.

Furthermore, there is a lack of standardization in how research defines "long-term success," meaning there is limited information for long-term outcomes that would provide a clear view of sustained symptomatic support. While the research describes patterns, it is important to remember that evidence highlights what is known — and what is still uncertain. Research continues to explore these areas, as research is ongoing to provide more context for conditions where symptoms may vary in intensity.

Key Studies & References

  1. Efficacy of ultramicronised diclofenac in patients with osteoarthritis – systematic review with network meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Meitan (FAQ)


Q: Is Meitan the same type of medicine as [similar drug class name]?

Official regulatory documents classify Meitan (Diclofenac) as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This classification means it works by targeting chemical processes in the body that cause pain and swelling.


Q: What is the most common side effect listed for Meitan?

According to the official product information, common side effects (those occurring in two percent or more of people in studies) may include fluid retention (edema), nausea, headache, dizziness, vomiting, and various forms of abdominal discomfort like diarrhea or constipation.


Q: Does Meitan have a 'black box' warning?

Yes, the official labeling from the U.S. Food and Drug Administration includes a Boxed Warning. This warning alerts patients and providers to the documented risk of serious cardiovascular thrombotic events (such as heart attack or stroke) and serious gastrointestinal adverse events (such as bleeding, ulceration, or perforation).


Q: Can Meitan be crushed or split?

Regulatory instructions state that specific controlled-release or enteric-coated tablets and capsules must be swallowed whole and should not be crushed, broken, or chewed. This ensures the medication maintains its specific release characteristics as defined by the manufacturer.


Q: Can older adults use Meitan?

Use of Meitan in older adults is possible but official sources advise extreme caution. This population faces a documented greater risk for serious adverse events, particularly gastrointestinal bleeding. The use of this medication in older adults is generally managed under close medical supervision.


Q: Are there research studies comparing Meitan to a placebo?

Yes, clinical studies referenced in regulatory documents often involve comparing Meitan to a neutral substance, known as a placebo. These Randomized Controlled Trials (RCTs) are a standard way for regulators to assess the drug's effectiveness and safety profile.


Q: Are changes in mood or behavior a side effect of Meitan?

The official label lists common central nervous system (CNS) effects such as dizziness and headache. Less common effects may include drowsiness or sleepiness. Other changes in mood or behavior are not typically listed among the most common adverse reactions in the official information.


Q: Can Meitan cause weight gain?

Unusually fast weight gain and swelling, known as edema or fluid retention, are listed as potential signs of serious side effects related to heart or kidney function. If this occurs, official patient information advises seeking immediate medical attention.


Q: Does Meitan interact with common cold or flu medications?

Official warnings cover interactions with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are common ingredients in some cold and flu medications. Concurrent use with other NSAIDs, often found in cold/flu medications, is typically discouraged in official documents due to increased risk.


Q: How quickly does Meitan start to work after I begin taking it?

The speed at which the medication reaches its maximum concentration in the body can vary depending on the specific product formulation. For example, immediate-release forms are designed to work faster than delayed-release forms. Taking the medication with food may also delay the absorption rate.


Q: What should I do if I forget to use Meitan one day?

Official patient information advises that if a dose is missed, it should be taken as soon as remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped and the regular schedule continued. The product information states that two doses should not be taken at the same time.


Q: Are there any specific foods or drinks to avoid while using Meitan?

The use of alcohol is strongly discouraged by regulatory documents, as it is documented to significantly increase the risk of gastrointestinal bleeding while using this medication. Additionally, taking certain oral formulations with food may delay the absorption of the medicine.


Q: Can Meitan cause tiredness or make me dizzy?

Yes, official adverse reaction reports classify dizziness as a common side effect. The labels also note that effects like sleepiness or drowsiness are possible, which is why caution is advised.


Q: How long is a typical course of treatment with Meitan?

For all forms, regulatory documents emphasize using the lowest effective dose for the shortest duration necessary. For severe, acute pain treated with an injectable solution, use is often limited to a maximum of two days. The duration of treatment for chronic conditions is determined by a healthcare provider.


Q: Is Meitan considered a controlled substance?

No, Meitan (Diclofenac) is officially classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is not designated as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other regulatory bodies.


Q: What does it mean that Meitan is an 'antagonist'?

The drug is officially described in regulatory documents as an inhibitor of the Cyclooxygenase (COX) enzyme, which means it blocks the enzyme's activity. It is also described as a modulator of nerve cell channels. While it acts to block a biological process, the term 'antagonist' is not the primary descriptor used on official labels.


Q: Can I take Meitan if I am also taking vitamins or supplements?

The label advises caution because Meitan can potentially affect the blood levels of other medications. Interactions with certain vitamins and supplements are possible, which is why official sources recommend discussing all products being taken with a healthcare provider.


Q: What is the risk of dependence or withdrawal with Meitan?

Meitan is a non-narcotic NSAID, and regulatory labeling does not list a risk of physical dependence or withdrawal upon stopping the medication.


Q: Is it true that Meitan needs to be taken at the same time every day?

Official administration instructions emphasize taking the medicine consistently as prescribed to maintain therapeutic levels in the body. While the necessity of precise daily timing varies by formulation, consistency in administration is generally noted to help maintain stable therapeutic levels.


Q: Can taking Meitan affect my ability to drive?

Yes, official patient information warns that Meitan may cause side effects such as dizziness or drowsiness. If these effects occur, patients should exercise caution regarding activities that require alertness, such as operating machinery or driving.


Q: Is Meitan used to treat other conditions besides its main purpose?

Yes, regulatory approvals confirm that Meitan (Diclofenac) is approved for a variety of conditions in addition to general pain relief, including certain types of arthritis, various kinds of acute pain, and migraines.


Q: What is the intended duration of action for Meitan?

The time it takes for the concentration of the active ingredient to drop by half (its half-life) is approximately two hours. However, the clinical duration of its pain-relieving and anti-inflammatory effects can vary from person to person.


Q: Does Meitan show up on standard drug tests?

Meitan (Diclofenac) is not a controlled substance and is not typically one of the substances screened for in standard workplace or forensic drug tests.


Q: Can Meitan be used during pregnancy?

Official labeling states that use is strictly contraindicated during the third trimester of pregnancy. Furthermore, regulatory documents indicate that use must be limited or avoided between approximately 20 and 30 weeks of pregnancy due to documented risks to the developing fetus.


Q: Are there known interactions between Meitan and herbal remedies?

Regulatory documents warn about potential interactions with various prescription drugs and other supplements. Because some herbal remedies can affect blood clotting or liver enzymes, official sources recommend exercising caution and consulting a medical professional regarding co-administration.


Q: Is Meitan recommended for children or adolescents?

Official information generally does not recommend systemic use (like oral tablets) for children under 14 to 16 years for most indications. However, topical formulations have received approval for use in adolescents aged 14 years and older for specific localized conditions.


Q: How often do people using Meitan experience side effects?

Official regulatory labels classify documented effects by their frequency in clinical studies. Some effects, such as headache, dizziness, and nausea, are listed as common, while serious events like stroke or gastrointestinal perforation are listed as rare or very rare.


Q: What is the chemical name of Meitan?

The active ingredient in Meitan, Diclofenac, has the official chemical name of 2-[2-(2,6-dichloroanilino)phenyl]acetic acid. This name describes the exact molecular structure of the compound.


Q: Why are there different strengths of Meitan available?

Different strengths (such as 50 mg or 75 mg) and formulations are available to allow healthcare providers to select the lowest effective dose needed to manage the patient's individual symptoms. This approach helps in minimizing the risk of adverse effects.


Q: Can Meitan be taken if I have kidney issues?

The medication is contraindicated in patients with advanced renal disease due to safety risks. Regulatory guidelines indicate that for those with milder impairment, dosing adjustments and close monitoring of kidney function may be needed.


Q: Why do people say Meitan is a 'first-line' treatment?

Meitan (Diclofenac) is widely recognized and is sometimes described in scientific and medical texts as a first-line therapy for certain acute and chronic pain conditions. This description is due to its documented anti-inflammatory and analgesic (pain-relieving) properties.


Q: Does the packaging for Meitan contain a patient information leaflet?

Yes, official regulatory labeling requires that a Patient Counseling Information leaflet or similar instructions for use be included with the prescription medication.


Q: What are the signs of a severe allergic reaction to Meitan?

Official safety information lists signs of a severe allergic reaction, which include breathing difficulties, wheezing, swelling of the face, lips, or throat, hives, severe itching, racing heart, and fever. These signs indicate the need for immediate medical assistance.

How should Meitan be stored and disposed of?

The storage and disposal of Meitan (Diclofenac) must align strictly with the conditions defined in official regulatory documents to maintain product stability and safety.

Official Storage Conditions

Storage Scope Labeled Requirements (Government Sources)
Temperature Store most forms at or below 30 C (e.g., 20 C to 25 C) [Controlled Room Temperature].
Environment Keep the medicine away from heat, moisture, and direct light. Do not freeze.
Packaging Store in the closed, original container, and dispense in a tight container.
Child Safety Mandatory: Keep out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired product must be done in accordance with local municipal and environmental requirements. If no local drug take-back program is available, the medicine (excluding certain high-risk forms) should be mixed with an undesirable substance, placed in a sealed container, and disposed of in household trash. Throwing medicine down the sink or toilet is not recommended unless specifically stated on the official product label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Meitan found in:

A-Z Index: